Condition
Ulcerative colitis news across medications, symptoms, monitoring, procedures, research, access, and daily life.
Page 32 of 40 · 1918 articles
This study identifies NR1D1 activation by the experimental drug SR9009 as a potential way to reduce inflammation and improve colon pathology in a mouse model of obesity-associated ulcerative colitis.
If confirmed, antibody signatures detectable years before symptoms could help identify people at higher risk for IBD and improve understanding of how the disease begins — a step toward earlier diagnosis or future...
Real-world data show how mirikizumab performs outside clinical trials, especially in patients previously exposed to multiple advanced therapies. That can help patients and clinicians weigh expectations for effectiveness...
Oat beta-glucan is a dietary fibre with prebiotic properties; the review suggests potential benefits seen in animal studies but shows human evidence is limited. Patients and clinicians may care because dietary fibres are...
Methotrexate is commonly used in IBD, often with biologics, but real‑world data on how long patients stay on it, typical dosing, and safety in large contemporary cohorts are limited.
Fear of movement was more common and more severe in people with ulcerative colitis in this study. Addressing kinesiophobia could help increase physical activity and improve function and quality of life for people with...
This study suggests tofacitinib may work quickly as a rescue option for biologic‑naive patients with steroid‑refractory ASUC and that many achieved steroid‑free remission by 24 weeks — information that could matter when...
This is an official prescribing-label update for an adalimumab biosimilar used to treat Crohn’s disease and ulcerative colitis, including pediatric indications and dosing. Changes to indications or pediatric dosing and...
Life satisfaction and social/work impacts are central to daily functioning for people with IBD. Knowing which social factors relate to lower satisfaction can help patients, caregivers, and clinicians spot who may need...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and JAK inhibitor. The original article is from Journal of Crohn's & colitis.
People with ulcerative colitis may be interested because ferulic acid is a plant-derived compound that, in lab and animal studies, appears to reduce gut inflammation, support the intestinal barrier, and positively...
Kidney and urinary problems (acute or chronic kidney injury and kidney stones) occurred in a notable minority of IBD patients in this study and were linked to prior IBD surgery, extensive UC, and cardiometabolic...
For patients and clinicians facing steroid- and infliximab-refractory acute severe ulcerative colitis, upadacitinib may be a third-line medical option that can produce rapid symptom and CRP improvement and allow some...
The study found disease-specific antibody changes years before IBD diagnosis, suggesting possible early biomarkers and new clues about how Crohn's disease and ulcerative colitis begin.
Cure8 indexed source-provided abstract text from JAMA, but this record did not meet the threshold for a full Cure8 brief. It is tagged for Ulcerative colitis, Inflammatory bowel disease, and Procedures and surgery.
The study identifies a specific polysaccharide fraction (VPS-30) that reduced inflammation and improved gut barrier markers in cell and mouse models of colitis, suggesting a possible new functional-food lead for...
Researchers and clinicians are exploring cGAS/STING as a novel immune pathway linked to mucosal barrier function and inflammation in UC. Modulators of this pathway could become future targeted treatments, so patients and...
Identifies macrophage-linked genes (CCL3, CCL4, JUNB) that are strongly upregulated in ulcerative colitis and may help explain immune-cell remodeling in the colon. These genes could serve as biomarkers or starting points...
This trial tests whether people with UC in deep remission can safely stop JAK inhibitor therapy — potentially reducing long-term exposure and associated safety concerns while preserving disease control and quality of...
The study will prospectively evaluate how often dysplasia occurs, how lesions look and behave after endoscopic resection, and what factors predict local or distant recurrence—information that could change surveillance...
The FDA label for dexamethasone explicitly lists regional enteritis (Crohn's disease) and ulcerative colitis among its gastrointestinal indications, and provides dosing guidance and steroid-equivalent tables that are...
The systems view could explain limits of single-cytokine therapies and point toward multi-layer, precision approaches that better match a patient’s specific immune, genetic, and microbial context.
If you or someone you care for has β‑thalassemia major, this report shows that inflammatory bowel diseases (Crohn’s disease and ulcerative colitis) can co-occur and may present diagnostic and management challenges.
The editorial outlines treatment strategies that could affect whether a person with ASUC avoids colectomy, highlights the importance of getting adequate infliximab exposure, and summarizes emerging drug classes that may...
A natural compound (diosgenin) reduced disease signs and inflammatory markers in a mouse model of ulcerative colitis, suggesting a possible anti-inflammatory mechanism that could inform future preclinical research.
Many people with IBD who achieve remission ask about reducing or stopping medication. This review summarises current evidence and highlights that withdrawal carries substantial relapse risk and that decisions should be...
Conversations about living with IBD and IBS can help people feel less isolated, learn practical coping strategies, and identify local support resources. Hearing from a specialist and from a caregiver can provide both...
A majority of surveyed IBD patients who use marijuana reported better quality of life and relief from symptoms such as nausea, joint pain, insomnia and anxiety — findings of interest to people seeking symptom management...
The review examines whether removing the appendix could change the course of ulcerative colitis — a potential surgical option that might lower colectomy or hospitalization risk in some scenarios but also carries...
The article points to plant-derived compounds with anti-inflammatory and antioxidant actions that may be relevant to colitis mechanisms, which could be of interest to patients and clinicians following experimental or...
For people with ulcerative colitis treated with infliximab for acute severe disease, whether to keep giving systemic corticosteroids afterward affects infection risk, steroid side effects, and disease control.
An LTE Phase 2 study offers longer-term safety monitoring and continued access to investigational long-acting antibody drugs for people who completed or met escape criteria in the parent SKYLINE-UC trial; that can matter...
This trial is testing a new experimental oral therapy (BRS201) aimed at reducing hydrogen sulfide–related metabolites in people with mild ulcerative colitis. If successful, the drug could represent a novel, non-biologic...
This trial tests etrasimod (an S1P receptor modulator) specifically in older adults with active ulcerative colitis — a group often underrepresented in IBD trials. Results could inform safety and short-term remission...
Patients with Crohn's disease had a higher adjusted risk of periprosthetic joint infection within 90 days after elective joint replacement, while ulcerative colitis did not. This difference could affect preoperative risk...
Targeting STING may reduce inflammatory signaling that contributes to ulcerative colitis; a safer, more potent STING inhibitor could become a new therapeutic approach if later-stage studies confirm benefit and safety.
This research links molecular subtypes of ulcerative colitis to infliximab (anti-TNF) response using an interpretable machine-learning method, which could help identify which patients are more or less likely to respond...
AI could help identify dietary patterns, predict which patients might benefit from specific nutrition approaches, and provide personalized nutrition support — potentially improving inflammation and gut microbiome...
This research describes a new nanoparticle/hydrogel delivery system that reduced inflammation and helped restore the intestinal barrier in mouse models of ulcerative colitis. It suggests a potential future therapeutic...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Chinese Journal of...
A cross‑trust histopathology MDT helped reclassify diagnoses in a substantial proportion of discussed paediatric IBD cases and occasionally changed management or transition planning, which could affect treatment...
Patients and clinicians often ask whether herbal formulas or plant compounds can help IBD. This preclinical study identifies quercetin and the PI3K–Akt pathway as potential mechanisms, which may guide future research...
The study suggests JAK and TYK2 inhibitors can directly change epithelial inflammatory signaling and proliferation in UC, which may be relevant to healing of the gut lining and how different drugs work beyond immune...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Tests and monitoring. The original article is from Cureus.
People with ulcerative colitis may be interested because synbiotic approaches aim to change the gut microbiome and intestinal barrier and therefore could become a future therapeutic option or adjunct. The paper...
People with UC who need biologic therapy during conception or pregnancy often face limited evidence about safety and effectiveness; this case suggests ustekinumab may be an option when other drugs fail or are stopped for...
The study links tissue and blood molecular changes to UC severity, suggesting candidate mechanisms (fibrogenesis, neutrophil activation) that could lead to biomarkers or new therapeutic targets. Understanding severity...
The study identifies a plant-derived compound that reduced inflammation and liver injury in a mouse model of ulcerative colitis and ties its effects to both JAK2/STAT1 inhibition and changes in the gut microbiota—two...
